Emerging Roles of Micrornas in Diabetic CardiomyopathyIngrid Fomison-Nurse and Rajesh Katare*
Department of Physiology-Heart Otgao, Otago School of Medical Sciences, University of Otago, Dunedin, 9010, New Zealand
- *Corresponding Author:
- Rajesh Katare
Department of Physiology-Heart Otago
Otago School of Medical Sciences
University of Otago, Dunedin
9010, New Zealand
E-mail: [email protected]
Received date: May 22, 2014; Accepted date: June 18, 2014; Published date: June 26, 2014
Citation: Nurse I F, Katare R (2014) Emerging Roles of Micrornas in Diabetic Cardiomyopathy. J Diabetes Metab 5:394. doi:10.4172/2155-6156.1000394
Copyright: © 2014 Nurse IF et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Ischaemic heart disease is an increasingly prevalent disease in the developed world, and accounts for a large degree of both morbidity and mortality in many countries. Diabetes Mellitus is also increasing in prevalence and as ischaemic heart disease is associated with Diabetes Mellitus, diabetic cardiomyopathy is an increasing problem globally. MicroRNAs are short, non-coding RNAs which negatively regulate gene expression through either translational repression or mRNA cleavage. These are found to exist in a stable form in both tissue and blood, and are specific to the tissue of origin. Cardiovascular miRNAs have been found to play roles in cardiac arrhythmogenesis, hypertrophy, and cardiac stem cell differentiation, as well as showing considerable links with diabetic cardiomyopathy. This interaction is important when considering the therapeutic potential of cardiovascular miRNAs, with possible therapeutic value in the treatment of vascular dysfunction, as well as the development of biomarkers for the early diagnosis and therefore treatment of the disease.